Exosomes in HNSCC Plasma as Surrogate Markers of Tumour Progression and Immune Competence

Clinical and Experimental Immunology - United Kingdom
doi 10.1111/cei.13157
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Separation of Plasma-Derived Exosomes Into CD3(+) and CD3(-) Fractions Allows for Association of Immune Cell and Tumor Cell Markers With Disease Activity in HNSCC Patients

Clinical and Experimental Immunology
AllergyImmunology
2018English

Serum DNA Microsatellites as Surrogate Genetic Markers of Breast Cancer Progression

2002English

Lymphocyte Subsets as Surrogate Markers in Antiretroviral Therapy

Infection
MedicineInfectious DiseasesMicrobiology
1991English

Exosomes From the Tumour-Adipocyte Interplay Stimulate Beige/Brown Differentiation and Reprogram Metabolism in Stromal Adipocytes to Promote Tumour Progression

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Biologically-Active Exosomes in Plasma of AML Patients Inhibit Innate Immunity and Promote Leukemia Progression

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Surrogate Markers of Antiangiogenic Therapies

2012English

Surrogate Markers for Cardiovascular Disease: Structural Markers

Circulation
Cardiovascular MedicinePhysiologyCardiology
2004English

Exosomes and Tumor-Mediated Immune Suppression

Journal of Clinical Investigation
Medicine
2016English

Serum Immune Markers and Disease Progression in an Incident Parkinson's Disease Cohort (ICICLE-PD)

Movement Disorders
Neurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy